Analysts' Actions: BAC, JCP, NTAP

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Bank of America ( BAC) was upgraded at Guggenheim from Neutral to Buy. $11 price target. Expect favorable first-quarter earnings, Guggenheim said.

Ball ( BLL) was initiated with a Hold rating at Keybanc. The stock is trading above its historical average valuation, Keybanc said.

Fidelity National ( FIS)was initiated with a Market Perform rating at Wells Fargo. Valuation call.

Endocyte ( ECYT) was initiated with a Sell rating at TheStreet Ratings.

Gamestop ( GME) was downgraded at Needham from Buy to Hold. Slower retail sales could hurt the company, Needham said.

JC Penney ( JCP) was initiated with a Neutral rating at UBS. $36 price target. Cost cuts should limit stock downside in the meantime, UBS said.

Nordstrom ( JWN) was initiated with a Buy rating at UBS. $63 price target. Hidden value supports a premium valuation, UBS said.

Kohl's ( KSS) was initiated with a Neutral rating at UBS. $53 price target. Growing pains still hurt, but capital strategy could change that, UBS said.

Macy's ( M) was initiated with a Neutral rating at UBS. $43 price target. SSS outperformance should continue, UBS said.

NetApp ( NTAP) was downgraded at FBN Securities from Outperform to Sector Perform. $45 price target. Channel checks suggest weaker sales, FBN said.

Pan American Silver Corp. ( PAAS) was downgraded to Hold at TheStreet Ratings.

Saks ( SKS) was initiated with a Neutral rating at UBS. $12 price target. Fixing legacy real estate issues key to driving fundamentals higher, UBS said.

Silicon Labs ( SLAB) was upgraded at Wunderlich from Hold to Buy. $50 price target. Selloff has created an attractive entry point, Wunderlich said.

Sterling Financial ( STSA) was initiated with a Market Perform rating at Keefe, Bruyette & Woods. Valuation call, based on a $19 price target, Keefe, Bruyette & Woods said.

Viropharma ( VPHM) was downgraded to Hold at Brean Murray. Vancocin will soon face heavy generic competition, Brean Murray said.

Yelp ( YELP) was initiated with a Neutral rating at Citigroup. $28 price target. Very robust valuation offsets significant market opportunity, Citigroup said.

Yelp was initiated with a Neutral rating at Goldman Sachs. $26 price target. Business model is still in its early stages, Goldman said.

Yelp was initiated with a Perform rating at Oppenheimer. $23 price target. Key metrics have material upside, Oppenheimer said.

Stock Comments / EPS Changes

Alcoa ( AA) estimates were raised at UBSthrough 2013. Improved outlook in the mid/downstream sectors, UBS said. Neutral rating.

Apple ( AAPL) estimates, target were boosted at Sterne Agee. Shares are now seen reaching $750. Estimates were also increased, following channel checks, Sterne Agee. Buy rating.

Ball numbers were raised at Jefferies. Shares are now seen reaching $49. Estimates also raised on favorable rigids volume trends, Jefferies said. Buy rating.

Canadian Pacific Railway ( CP) numbers were raised at Jefferies. Shares are now seen reaching $72. Estimates were also raised on first-quarter guidance, Jefferies said. Hold rating.

Forest Labs ( FRX) numbers were cut at Credit Suisse. Shares are now seen reaching $44. Estimates were also reduced, given the company's new guidance, Credit Suisse said. Outperform rating.

First Solar ( FSLR) numbers were cut at UBS. Shares are now seen reaching $23. Estimates were also lowered as module business is affecting system value, UBS said. Neutral rating.

Las Vegas Sands ( LVS) numbers were increased at BMO Capital. Estimates were raised through 2013. Macau should continue to drive growth, BMO Capital said. Outperform rating and new $69 price target.

Priceline.com ( PCLN) numbers were raised at Benchmark. Shares are now seen reaching $840. Estimates were also increased, given better industry trends and emerging market growth, Benchmark said. Buy rating.

Qlik Technologies ( QLIK) price target was raised at Jefferies to $35. Survey suggests modest upside risk, Jefferies said. Buy rating.

VMware ( VMW) price target was raised at Jefferies to $100. Improved current year growth expectations, Jefferies said. Hold rating.

ViroPharma Incorporated ( VPHM) numbers were lowered at Jefferies. Shares are now seen reaching $33. Estimates were also lowered on FDA approval of generic Vancocin, Jefferies said. Buy rating.

ViroPharma Incorporated numbers were lowered at Oppenheimer. Shares are now seen reaching $27. Estimates were also lowered on denial of Citizen's Petition related to Vancocin, Oppenheimer said. Outperform rating.

>To submit a news tip, email: tips@thestreet.com.

READERS ALSO LIKE:


Follow TheStreet on Twitter and become a fan on Facebook.

This article was written by a staff member of TheStreet.

More from Stocks

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Tesla's Supercharger Network Is Booming -- Here's Why That's a Concern

Tesla's Supercharger Network Is Booming -- Here's Why That's a Concern

Attention 60 Minutes: Google Isn't the Only Big-Tech Monopoly

Attention 60 Minutes: Google Isn't the Only Big-Tech Monopoly

Tesla CEO Elon Musk Is a Rock Star: Kiss Icon Gene Simmons

Tesla CEO Elon Musk Is a Rock Star: Kiss Icon Gene Simmons

The Best Investment Advice? Stay Diversified

The Best Investment Advice? Stay Diversified